Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
Fiche publication
Date publication
décembre 2021
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Magro F, Magalhaes D, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Santiago M, Dias S, Alves C, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC,
Lien Pubmed
Résumé
Subclinical intestinal inflammation is common in Crohn's disease (CD). We aimed to explore its impact in the disease progression of infliximab-treated patients and the usefulness of fecal calprotectin (FC) and C-reactive protein (CRP) as surrogate minimally invasive biomarkers.
Mots clés
Anti-TNF-α, C-Reactive Protein, Fecal Calprotectin, Inflammatory Bowel Disease
Référence
Clin Gastroenterol Hepatol. 2021 Dec 9;: